Short-term outcomes of enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma: Real-world use in multicenter cohort regardless of cisplatin eligibility
Takuji Hayashi, Atsunari Kawashima, Yoshiyuki Yamamoto, Yu Ishizuya et autres
jp (code pays fourni par la source)